Across TCGA pan-cancer cohorts, SPANXD Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPANXD data layer compared with 17 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPANXD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPANXD expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, SARC, and UCEC are the cancer types where SPANXD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.115	0.756	<.001	36	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
UCEC	DFS	Median	All	1.000	0.628	.023	6	view →
SKCM	DFS	Median	All	0.582	0.735	.024	5	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SPANXD tumor-vs-normal RNA expression · all SPANXD data types